FOXM1-derived peptide, and vaccine including same

A method of inducing a CTL(s), which comprises a step selected from the group consisting of:

• (a) co-culturing a CD8-positive T cell(s) with an APC(s) that presents on its surface a complex of an HLA antigen and a peptide;
• and (b) co-culturing a CD8-positive T cell(s) with an exosome(s) that presents on its surface a complex of an HLA antigen and the peptide;
• wherein the peptide is not phosphorylated, wherein the peptide has cytotoxic T cell (CTL)-inducing ability in an HLA-A01-restrictive manner, and wherein the peptide comprises an amino acid sequence selected from the group consisting of:
• (i) the amino acid sequence of SEQ ID NO:
• 56, and
• (ii) the amino acid sequence of SEQ ID NO:
• 56 into which one or two amino acid substitutions are introduced.

A method of inducing an immune response against cancer, which comprises administering to a subject at least one ingredient selected from the group consisting of (a) to (d) below:

• (a) a peptide;
• (b) a polynucleotide encoding the peptide in an expressible form;
• (c) an APC that presents on its cell surface a complex of the peptide and an HLA antigen;
• and (d) an exosome that presents on its surface a complex of the peptide and an HLA antigen;
• wherein the peptide is not phosphorylated, wherein the peptide has cytotoxic T cell (CTL)-inducing ability in an HLA-A01-restrictive manner, and wherein the peptide comprises an amino acid sequence selected from the group consisting of:
• (i) the amino acid sequence of SEQ ID NO:
• 56, and
• (ii) the amino acid sequence of SEQ ID NO:
• 56 into which one or two amino acid substitutions are introduced.

A method of treating cancer, which comprises administering to a subject at least one ingredient selected from the group consisting of (a) to (d) below:

• (a) a peptide;
• (b) a polynucleotide encoding the peptide in an expressible form;
• (c) an APC that presents on its cell surface a complex of the peptide and an HLA antigen;
• and (d) an exosome that presents on its surface a complex of the peptide and an HLA antigen;
• wherein the peptide is not phosphorylated, wherein the peptide has cytotoxic T cell (CTL)-inducing ability in an HLA-A01-restrictive manner, and wherein the peptide comprises an amino acid sequence selected from the group consisting of:
• (i) the amino acid sequence of SEQ ID NO:
• 56, and
• (ii) the amino acid sequence of SEQ ID NO:
• 56 into which one or two amino acid substitutions are introduced.

An emulsion comprising a peptide, a water-soluble carrier and an oil adjuvant in an amount effective for enhancing cellular immunity,

• wherein the peptide is not phosphorylated, wherein the peptide has cytotoxic T cell (CTL)-inducing ability in an HLA-A01-restrictive manner, and wherein the peptide comprises an amino acid sequence selected from the group consisting of:
• (i) the amino acid sequence of SEQ ID NO:
• 56, and
• (ii) the amino acid sequence of SEQ ID NO:
• 56 into which one or two amino acid substitutions are introduced.